We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Blueprint Medicines Corporation | NASDAQ:BPMC | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.345 | -0.30% | 114.625 | 114.37 | 115.08 | 116.75 | 114.59 | 116.25 | 27,587 | 15:06:02 |
From Jul 2022 to Jul 2024
By Denny Jacob
Blueprint Medicines on Monday said the Food and Drug Administration approved ayvakit as a treatment for adults with indolent systemic mastocytosis, a hematologic disorder that can have debilitating symptoms across multiple organs.
The precision therapy company said ayvakit has been FDA approved for the treatment of advanced systemic mastocytosis since June 2021.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 22, 2023 17:12 ET (21:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Blueprint Medicines Chart |
1 Month Blueprint Medicines Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
